FLX is an SSRI known to increase TGF-β1 concentrations in rodents (Torrisi et al., 2019), but no studies have been conducted in human cells to examine whether this drug can rescue TGF-β1 concentrations in the culture media of PBMCs from individuals with DS. This evidence concerns the gene TGFB1 and Dravet syndrome.